Universe Pharmaceuticals's Days Sales Outstanding for the
six
months ended in Sep. 2025 was 242.94.
Universe Pharmaceuticals's Days Inventory for the
six
months ended in Sep. 2025 was 94.36.
Universe Pharmaceuticals's Days Payable for the
six
months ended in Sep. 2025 was 148.63.
Therefore, Universe Pharmaceuticals's Cash Conversion Cycle (CCC) for the
six
months ended in Sep. 2025 was 188.67.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Universe Pharmaceuticals Cash Conversion Cycle Related Terms
Universe Pharmaceuticals Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Universe Pharmaceuticals's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs CBIH, PRFX, IMCC: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Universe Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals (UPC) has a Cash Conversion Cycle of 188.67 as of Sep. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Universe Pharmaceuticals and its competitors.
Is Universe Pharmaceuticals' Cash Conversion Cycle too high?
Universe Pharmaceuticals' current Cash Conversion Cycle is 188.67. The Drug Manufacturers industry median Cash Conversion Cycle is 145.72. Universe Pharmaceuticals' value of 188.67 is 29.5% above this industry median. Overall, Universe Pharmaceuticals has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Cash Conversion Cycle compare to CBIH and PRFX?
Universe Pharmaceuticals' Cash Conversion Cycle of 188.67 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.72. Universe Pharmaceuticals' value of 188.67 is 29.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.72, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current Cash Conversion Cycle of 188.67 is 29.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current Cash Conversion Cycle is 188.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Possible Value Trap. The stock's GF Value™ is $5.22, compared to a current price of $2.84 — trading 45.6% below its estimated fair value. The current Cash Conversion Cycle is 188.67 and 29.5% above the Drug Manufacturers industry median of 145.72. Universe Pharmaceuticals' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Cash Conversion Cycle is 188.67 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be undervalued.
The current stock price of $2.84 is trading 45.6% below its estimated GF Value™ of $5.22.
GuruFocus considers Universe Pharmaceuticals to be Possible Value Trap.
Key valuation signals for UPC:
Cash Conversion Cycle: 188.67
GF Value™: $5.22 vs. price of $2.84 (45.6% below fair value)
Industry Position: 29.5% above the Drug Manufacturers median
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
58GF Score
Get the complete analysis for UPC
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
